Bristol Myers Squibb’s mezigdomide has scored its first phase 3 win, with the Cereblon E3 ligase modulator (CELMoD) tied to a statistically significant improvement in progression-free survival (PFS) ...
A phase 3 trial of Biokin’s bispecific antibody-drug conjugate (ADC) has hit at least one primary endpoint, boosting the prospects of a candidate that Bristol Myers Squibb licensed outside of China ...
Bristol Myers Squibb hasn’t splashed out as much money as some of its peers in the fast-growing field of antibody drug conjugate (ADC) cancer therapies, but the pharmaceutical giant just struck a deal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results